Parameter | Whole group (n = 150) | CRSwNP with asthma (n = 80) | CRSwNP without asthma (n = 70) | P value |
---|---|---|---|---|
Inflammatory cell type in nasal polyps† | ||||
Lymphocyte, cells/HP | 76.9 (40.0, 150.0) | 71.0 (39.3, 122.0) | 82.7 (44.0, 180.0) | 0.232 |
Lymphocyte, % | 39.3 ± 22.6 | 37.1 ± 21.2 | 42.9 ± 24.6 | 0.163 |
Plasma cel, cells/HP | 30.0 (16.4, 52.8) | 30.0 (18.7, 58.7) | 30.0 (10.0, 40.0) | 0.279 |
Plasma cell, % | 12.5 (6.6, 20.9) | 14.4 (6.8, 24.7) | 10.3 (5.3, 18.2) | 0.162 |
Eosinophil, cells/HP | 80.0 (27.0, 200.0) | 80.0 (30.0, 201.8) | 70.0 (15.3, 180.0) | 0.563 |
Eosinophil, % | 37.3 (12.9, 65.1) | 38.8 (16.7, 66.7) | 30.9 (9.7, 54.5) | 0.160 |
Neutrophil, cells/HP | 0.7 (0.0, 10.0) | 0.3 (0.0, 10.0) | 3.7 (0.0, 20.0) | 0.183 |
Neutrophil, % | 0.3 (0.0, 3.9) | 0.3 (0.0, 3.6) | 1.3 (0.0, 7.1) | 0.219 |
Eosinophil ≥ 10%, n (%) | 101 (80.2) | 67 (84.8) | 34 (72.3) | 0.090 |
Eosinophil > 27%, n (%) | 80 (63.5) | 54 (68.4) | 26 (55.3) | 0.142 |
Spirometry | ||||
FEV1/FVC, % | 83.4 (80.4, 89.0) | 81.3 (68.3, 85.9) | 82.9 (82.8, 90.9) | < 0.001* |
FEV1%predicted, % | 93.1 ± 17.8 | 87.2 ± 19.4 | 99.9 ± 12.8 | < 0.001* |
Medication before enrolment | ||||
Not taking drugs, n (%) | 22 (14.7) | 1 (1.3) | 21 (30.0) | < 0.001* |
Topical corticosteroids, n (%) | 120 (80.0) | 79(98.8) | 41 (58.6) | < 0.001* |
Leukotriene receptor antagonist, n (%) | 72 (48.0) | 45 (56.3) | 27 (38.6) | 0.031* |
Antihistamines, n (%) | 60 (40.0) | 28 (35.0) | 32(45.7) | 0.181 |